NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Historical Holders from Q1 2014 to Q1 2025

Symbol
NBIX on Nasdaq
CUSIP
64125C109
Type / Class
Equity / Common Stock
Shares outstanding
99.8M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
94.3M
Holdings value
$12.9B
% of all portfolios
0.014%
Grand Portfolio weight change
+0.001%
Number of holders
590
Number of buys
292
Number of sells
-276
Average Value change %
0%
Average buys %
+0.004%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10.15% $1.12B 10.1M The Vanguard Group Feb 28, 2025
STATE STREET CORP 4.8% $541M 4.89M STATE STREET CORPORATION Dec 31, 2024

Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 1.41M $156M +$54.3M $110.60 74
2024 Q4 94.3M $12.9B +$279M $136.50 590
2024 Q3 92.6M $10.7B -$221M $115.22 567
2024 Q2 93.7M $12.9B +$111M $137.67 588
2024 Q1 92.9M $12.8B +$99.4M $137.92 578
2023 Q4 92.2M $12.1B -$103M $131.76 532
2023 Q3 91.6M $10.3B +$20M $112.50 498
2023 Q2 89.6M $8.46B +$8.43M $94.30 441
2023 Q1 90.7M $9.17B +$82.7M $101.22 472
2022 Q4 89.8M $10.7B +$125M $119.44 517
2022 Q3 89.2M $9.47B -$94.9M $106.21 441
2022 Q2 88.9M $8.66B -$6.4M $97.48 413
2022 Q1 86.5M $8.11B +$147M $93.75 401
2021 Q4 88.9M $7.56B -$136M $85.17 383
2021 Q3 89.9M $8.63B -$73M $95.91 381
2021 Q2 91.2M $8.87B -$391M $97.32 394
2021 Q1 94.8M $9.21B +$550M $97.25 404
2020 Q4 89.3M $8.56B -$6.53M $95.85 385
2020 Q3 88.4M $8.5B -$166M $96.16 399
2020 Q2 90.8M $11.1B +$57.4M $122.00 404
2020 Q1 90.4M $7.83B +$142M $86.55 353
2019 Q4 88.8M $9.55B -$106M $107.49 379
2019 Q3 89.5M $8.07B +$132M $90.11 320
2019 Q2 88.9M $7.5B +$476M $84.43 293
2019 Q1 88.3M $7.78B -$77.1M $88.10 318
2018 Q4 89.5M $6.37B -$87.2M $71.41 318
2018 Q3 88.6M $10.9B -$352M $122.95 337
2018 Q2 91.1M $8.95B +$109M $98.24 269
2018 Q1 92M $7.63B -$153M $82.93 258
2017 Q4 89.1M $6.91B -$128M $77.59 255
2017 Q3 96M $5.88B +$104M $61.28 219
2017 Q2 94.9M $4.36B +$625M $46.00 219
2017 Q1 84.8M $3.67B +$230M $43.30 212
2016 Q4 84.1M $3.26B -$79.5M $38.70 217
2016 Q3 85.7M $4.34B +$54.8M $50.64 235
2016 Q2 84.8M $3.86B -$118M $45.45 223
2016 Q1 87.6M $3.46B +$138M $39.55 208
2015 Q4 83.4M $4.72B +$48.3M $56.57 215
2015 Q3 82.8M $3.29B -$26.8M $39.79 202
2015 Q2 82.3M $3.93B -$83.6M $47.76 193
2015 Q1 85.2M $3.38B +$406M $39.71 170
2014 Q4 75.2M $1.68B +$53.1M $22.34 131
2014 Q3 73.3M $1.15B +$44.8M $15.67 132
2014 Q2 70.4M $1.04B +$24.6M $14.84 123
2014 Q1 69.7M $1.12B +$195M $16.10 121